Beneficial effect of 4-methylumbelliferone against bile duct ligation-induced hepatic fibrosis in rats

DOI 機関リポジトリ HANDLE Web Site
  • Sawada Naoya
    Department of Gastroenterology and Hematology, Hirosaki Graduate School of Medicine
  • Mikami Kenichiro
    Department of Gastroenterology and Hematology, Hirosaki Graduate School of Medicine
  • Igarashi Go
    Department of Gastroenterology and Hematology, Hirosaki Graduate School of Medicine
  • Endo Tetsu
    Department of Gastroenterology and Hematology, Hirosaki Graduate School of Medicine
  • Sato Ken
    Department of Gastroenterology and Hematology, Hirosaki Graduate School of Medicine
  • Kakizaki Ikuko
    Department of Glycotechnology, Hirosaki University Graduate School of Medicine
  • Fukuda Shinsaku
    Department of Gastroenterology and Hematology, Hirosaki Graduate School of Medicine

この論文をさがす

抄録

Background & Aims: Liver fibrosis progresses to cirrhosis as the consequence of chronic liver injury. 4-methylumbelliferone (4-MU), a derivative of coumarin, has been used as an approved drug to treat biliary spasm. Recent publications have reported that 4-MU inhibits production of hyaluronan (HA), which is a key component of extracellular matrix deposition in fibrotic and cirrhotic liver. We investigated the effect of 4-MU on fibrotic liver in rats.<br> Methods: Liver fibrosis was induced by bile duct ligation (BDL). Male Sprague-Dawley rats received a standard diet or the same diet containing 1% or 5% of 4-MU from 1 week before BDL. The rats were sacrificed at 3 weeks after BDL.<br> Results: Administration of 4-MU increased serum 4-MU concentration levels, thereby decreasing serum HA levels in a dose-dependent manner. 4-MU treatment suppressed liver fibrosis in interlobular and pericentral areas with reduced alpha-smooth muscle actin expression, which suggested hepatic stellate cell activation.<br> Conclusion: Treatment with 4-MU suppressed the experimental hepatic fibrosis accompanied by inhibition of HA production. Although further experimental studies are needed, 4-MU could protect against fibrogenesis and may be repurposed as a safe therapeutic application for hepatic fibrosis.

収録刊行物

  • 弘前医学

    弘前医学 66 (2-4), 143-151, 2016

    弘前大学大学院医学研究科・弘前医学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ